# Inhaled Isoflurane for Sedation of Invasively Ventilated Patients With Cardiogenic Shock on Extracorporeal Membrane Oxygenation

Study · id `cardio:ct-nct07099014` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07099014](<https://clinicaltrials.gov/study/NCT07099014>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07099014

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07099014. Randomized; no masking; primary purpose treatment. Start 2025-09-15 (anticipated); primary completion 2028-10-13 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07099014, source copy `cardio:ctgov-nct07099014-2025-08-01`, retrieved 2026-10-31)
- Planned start: 2025-09-15 (anticipated) (ClinicalTrials.gov record NCT07099014, source copy `cardio:ctgov-nct07099014-2025-08-01`, retrieved 2026-10-31)
- Primary completion: 2028-10-13 (anticipated) (ClinicalTrials.gov record NCT07099014, source copy `cardio:ctgov-nct07099014-2025-08-01`, retrieved 2026-10-31)
- Completion: 2029-04-13 (anticipated) (ClinicalTrials.gov record NCT07099014, source copy `cardio:ctgov-nct07099014-2025-08-01`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07099014-2025-08-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Inhaled Isoflurane for Sedation of Invasively Ventilated Patients With Cardiogenic Shock on Extracorporeal Membrane Oxygenation
- Acronym: INSEPTION
- Condition: Cardiogenic Shock, ECMO
- Intervention (Drug): Inahled Isoflurane
- Intervention (Drug): Propofol, midazolam
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 3fbc82df01f91c9b1141514a52aa0515ea4621c4fa94ff54756a446563276cfc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
